Displaying drugs 11426 - 11450 of 11608 in total
Sonpiretigene isteparvovec
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
Investigational
Matched Description: … [L46676] Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three …
Gabexate
Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]
Investigational
Matched Description: … Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. …
Serrapeptase
Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).
Investigational
Matched Description: … Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular …
Pinatuzumab vedotin
Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
Investigational
Matched Description: … Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin …
RO7300490
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics …
Nicotinamide Mononucleotide
3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]
Experimental
Matched Description: … A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C- …
BF-37
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct …
SB-269970
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]
Investigational
Matched Description: … In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective …
(S)-Warfarin
Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.
Experimental
Investigational
Matched Description: … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared …
Hu-rhEGF-rP64k/Mont
Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically …
Jaktinib
Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Investigational
Matched Description: … Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. …
NSI-566
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
Matched Description: … NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. …
RG2417
RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential for cell metabolism. Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy...
Investigational
Matched Description: … RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of …
MM-093
MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults and children. Research on AFP suggests that it may play a role in modulating the immune system of...
Investigational
Matched Description: … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein ... Research on AFP suggests that it may play a role in modulating the immune system of the mother in order …
INO-4800
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.[A214475, A214478] Follow up studies in both...
Investigational
Matched Description: … [A214475]
A Phase 1 clinical trial for INO-4800 in the U.S. ... INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development ... [L14372] A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced …
EPC2407
EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors
include the frequently occurring cancers of the lung,...
Investigational
Matched Description: … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of …
Fenspiride
Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as...
Experimental
Matched Description: … Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory …
NOV-002
NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Investigational
Matched Description: … NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy …
Etiprednol dicloacetate
Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease. Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture.
Investigational
Matched Description: … Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has …
Myrcludex B
Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).
Investigational
Matched Description: … Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized …
mRNA-3927
mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid nanoparticle (LNP). Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.
Investigational
Matched Description: … alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a …
Trafermin
Investigational
Zosuquidar
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Description: … Zosuquidar is a compound of antineoplastic drug candidates currently under development. …
Displaying drugs 11426 - 11450 of 11608 in total